[Clinical characteristics and potential prognostic factors of breast cancer patients with liver metastases].

Article Details

Citation

Copy to clipboard

Wang JY, Xu BH, Tian LJ, Wang Y

[Clinical characteristics and potential prognostic factors of breast cancer patients with liver metastases].

Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):612-6.

PubMed ID

17236558 [ View in PubMed

]

Abstract

OBJECTIVE: To analyze the clinical characteristics, efficiency of treatment and potential prognostic factors of breast cancer patients with liver metastases (BCLM). METHODS: The data of clinical characteristics, response to treatment and survival were retrospectively analyzed in 152 breast cancer patients with liver metastasis using SPSS 11.5. RESULTS: The median disease free survival (DFS), the median survival of recurrence (MSR) and median time to progress (TTP) of this series was 21 months, 16 months and 7.4 months, respectively. The response rate in chemotherapy group was higher than that in the transcatheter arterial chemoembolization (TACE) group (37.7% vs. 53%, P = 0. 039). The TTP was longer (7 m vs. 10 m, P = 0.048) and the response rate (63.3% vs. 40.0%, P = 0.04) in taxanes-based chemotherapy group was significantly higher than that in non-taxanes-containing regimen. The MSR in patients with single liver metastases treated by TACE was longer than that by chemotherapy (16 m vs. 30 m, P = 0.0052), but it was not observed in the patients with multiple metastases. Pathological tumor size (PT) and axillary lymph node status at diagnosis, negative estrogen receptor (ER) status, abnormal ALT level induced by liver metastases, metastastic tumor size were significantly correlated with shorter survival. CONCLUSION: The effective chemotherapy especially the taxane-containing regimen and TACE may improve outcome for breast cancer patient with liver metastasis.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Chlorotrianisene	Estrogen receptor alpha	Protein	Humans	Yes	Agonist	Details